nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—thyroid cancer	0.588	1	CbGaD
Lenalidomide—CDH5—trachea—thyroid cancer	0.00626	0.125	CbGeAlD
Lenalidomide—TNFSF11—head—thyroid cancer	0.00584	0.117	CbGeAlD
Lenalidomide—CRBN—saliva-secreting gland—thyroid cancer	0.00516	0.103	CbGeAlD
Lenalidomide—CDH5—thyroid gland—thyroid cancer	0.00496	0.099	CbGeAlD
Lenalidomide—CDH5—head—thyroid cancer	0.0044	0.0879	CbGeAlD
Lenalidomide—TNFSF11—lymph node—thyroid cancer	0.00409	0.0818	CbGeAlD
Lenalidomide—CRBN—trachea—thyroid cancer	0.00398	0.0795	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—EPO—thyroid cancer	0.00356	0.123	CbGpPWpGaD
Lenalidomide—CRBN—thyroid gland—thyroid cancer	0.00315	0.0629	CbGeAlD
Lenalidomide—CDH5—lymph node—thyroid cancer	0.00308	0.0615	CbGeAlD
Lenalidomide—PTGS2—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00288	0.0998	CbGpPWpGaD
Lenalidomide—CRBN—head—thyroid cancer	0.00279	0.0558	CbGeAlD
Lenalidomide—Pomalidomide—PTGS2—thyroid cancer	0.00267	0.608	CrCbGaD
Lenalidomide—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00216	0.075	CbGpPWpGaD
Lenalidomide—CRBN—lymph node—thyroid cancer	0.00196	0.0391	CbGeAlD
Lenalidomide—Thalidomide—PTGS2—thyroid cancer	0.00172	0.392	CrCbGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.00129	0.0447	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—CDK1—thyroid cancer	0.00123	0.0425	CbGpPWpGaD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00118	0.0408	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—CDK1—thyroid cancer	0.00116	0.0401	CbGpPWpGaD
Lenalidomide—PTGS2—trachea—thyroid cancer	0.00108	0.0217	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—thyroid cancer	0.00101	0.0349	CbGpPWpGaD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—AKT1—thyroid cancer	0.00083	0.0288	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000781	0.0271	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.000764	0.0265	CbGpPWpGaD
Lenalidomide—PTGS2—head—thyroid cancer	0.00076	0.0152	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—AKT1—thyroid cancer	0.000724	0.0251	CbGpPWpGaD
Lenalidomide—ABCB1—trachea—thyroid cancer	0.00067	0.0134	CbGeAlD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—AKT1—thyroid cancer	0.000638	0.0221	CbGpPWpGaD
Lenalidomide—PTGS2—lymph node—thyroid cancer	0.000532	0.0106	CbGeAlD
Lenalidomide—ABCB1—thyroid gland—thyroid cancer	0.00053	0.0106	CbGeAlD
Lenalidomide—ABCB1—head—thyroid cancer	0.00047	0.0094	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NRAS—thyroid cancer	0.00044	0.0152	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—NRAS—thyroid cancer	0.000415	0.0144	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—thyroid cancer	0.000408	0.0142	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CALCB—thyroid cancer	0.000382	0.0133	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—KRAS—thyroid cancer	0.000379	0.0131	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TRIM33—thyroid cancer	0.000362	0.0126	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—KRAS—thyroid cancer	0.000357	0.0124	CbGpPWpGaD
Lenalidomide—ABCB1—lymph node—thyroid cancer	0.000329	0.00658	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—HRAS—thyroid cancer	0.000322	0.0112	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—HRAS—thyroid cancer	0.000304	0.0105	CbGpPWpGaD
Lenalidomide—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000286	0.00991	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—AKT1—thyroid cancer	0.000284	0.00985	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—AKT1—thyroid cancer	0.000268	0.0093	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000255	0.00883	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.000254	0.00879	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TCF7L1—thyroid cancer	0.000242	0.00838	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.000224	0.00776	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.0002	0.00693	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000178	0.00618	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TSHR—thyroid cancer	0.000177	0.00614	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PRKAR1A—thyroid cancer	0.000174	0.00604	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000172	0.00596	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MEN1—thyroid cancer	0.000166	0.00577	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	0.000153	0.0053	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTCH1—thyroid cancer	0.000151	0.00522	CbGpPWpGaD
Lenalidomide—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000144	0.000436	CcSEcCtD
Lenalidomide—Dry skin—Doxorubicin—thyroid cancer	0.000142	0.000433	CcSEcCtD
Lenalidomide—Pancreatitis—Epirubicin—thyroid cancer	0.000142	0.000433	CcSEcCtD
Lenalidomide—Vomiting—Sorafenib—thyroid cancer	0.000142	0.000432	CcSEcCtD
Lenalidomide—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000142	0.000431	CcSEcCtD
Lenalidomide—Hypokalaemia—Doxorubicin—thyroid cancer	0.000141	0.00043	CcSEcCtD
Lenalidomide—Angina pectoris—Epirubicin—thyroid cancer	0.000141	0.00043	CcSEcCtD
Lenalidomide—Rash—Sorafenib—thyroid cancer	0.000141	0.000428	CcSEcCtD
Lenalidomide—Dermatitis—Sorafenib—thyroid cancer	0.000141	0.000428	CcSEcCtD
Lenalidomide—Breast disorder—Doxorubicin—thyroid cancer	0.00014	0.000427	CcSEcCtD
Lenalidomide—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00014	0.000425	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00014	0.000425	CcSEcCtD
Lenalidomide—Headache—Sorafenib—thyroid cancer	0.00014	0.000425	CcSEcCtD
Lenalidomide—Bronchitis—Epirubicin—thyroid cancer	0.00014	0.000424	CcSEcCtD
Lenalidomide—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000139	0.000422	CcSEcCtD
Lenalidomide—Pancytopenia—Epirubicin—thyroid cancer	0.000138	0.000419	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—SST—thyroid cancer	0.000138	0.00477	CbGpPWpGaD
Lenalidomide—Gastritis—Doxorubicin—thyroid cancer	0.000138	0.000418	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000137	0.000417	CcSEcCtD
Lenalidomide—Muscular weakness—Doxorubicin—thyroid cancer	0.000137	0.000417	CcSEcCtD
Lenalidomide—Neutropenia—Epirubicin—thyroid cancer	0.000136	0.000413	CcSEcCtD
Lenalidomide—Dysuria—Epirubicin—thyroid cancer	0.000136	0.000413	CcSEcCtD
Lenalidomide—Abdominal distension—Doxorubicin—thyroid cancer	0.000135	0.000411	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000135	0.00041	CcSEcCtD
Lenalidomide—Asthma—Doxorubicin—thyroid cancer	0.000134	0.000408	CcSEcCtD
Lenalidomide—Influenza—Doxorubicin—thyroid cancer	0.000134	0.000408	CcSEcCtD
Lenalidomide—Dysphagia—Doxorubicin—thyroid cancer	0.000134	0.000408	CcSEcCtD
Lenalidomide—Pollakiuria—Epirubicin—thyroid cancer	0.000134	0.000408	CcSEcCtD
Lenalidomide—Nausea—Sorafenib—thyroid cancer	0.000133	0.000403	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000133	0.000403	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CALCA—thyroid cancer	0.000133	0.00459	CbGpPWpGaD
Lenalidomide—Weight increased—Epirubicin—thyroid cancer	0.000132	0.000402	CcSEcCtD
Lenalidomide—Pancreatitis—Doxorubicin—thyroid cancer	0.000132	0.0004	CcSEcCtD
Lenalidomide—Weight decreased—Epirubicin—thyroid cancer	0.000131	0.000399	CcSEcCtD
Lenalidomide—Hyperglycaemia—Epirubicin—thyroid cancer	0.000131	0.000398	CcSEcCtD
Lenalidomide—Angina pectoris—Doxorubicin—thyroid cancer	0.000131	0.000398	CcSEcCtD
Lenalidomide—Pneumonia—Epirubicin—thyroid cancer	0.00013	0.000396	CcSEcCtD
Lenalidomide—Infestation NOS—Epirubicin—thyroid cancer	0.000129	0.000393	CcSEcCtD
Lenalidomide—Infestation—Epirubicin—thyroid cancer	0.000129	0.000393	CcSEcCtD
Lenalidomide—Bronchitis—Doxorubicin—thyroid cancer	0.000129	0.000393	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000128	0.00039	CcSEcCtD
Lenalidomide—Pancytopenia—Doxorubicin—thyroid cancer	0.000128	0.000388	CcSEcCtD
Lenalidomide—Renal failure—Epirubicin—thyroid cancer	0.000127	0.000387	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000127	0.000386	CcSEcCtD
Lenalidomide—Stomatitis—Epirubicin—thyroid cancer	0.000126	0.000383	CcSEcCtD
Lenalidomide—Conjunctivitis—Epirubicin—thyroid cancer	0.000126	0.000382	CcSEcCtD
Lenalidomide—Urinary tract infection—Epirubicin—thyroid cancer	0.000126	0.000382	CcSEcCtD
Lenalidomide—Neutropenia—Doxorubicin—thyroid cancer	0.000126	0.000382	CcSEcCtD
Lenalidomide—Dysuria—Doxorubicin—thyroid cancer	0.000126	0.000382	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000125	0.000379	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000124	0.00431	CbGpPWpGaD
Lenalidomide—Sweating—Epirubicin—thyroid cancer	0.000124	0.000377	CcSEcCtD
Lenalidomide—Pollakiuria—Doxorubicin—thyroid cancer	0.000124	0.000377	CcSEcCtD
Lenalidomide—Haematuria—Epirubicin—thyroid cancer	0.000123	0.000375	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000123	0.000373	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000122	0.000372	CcSEcCtD
Lenalidomide—Weight increased—Doxorubicin—thyroid cancer	0.000122	0.000372	CcSEcCtD
Lenalidomide—Epistaxis—Epirubicin—thyroid cancer	0.000122	0.000371	CcSEcCtD
Lenalidomide—Weight decreased—Doxorubicin—thyroid cancer	0.000122	0.000369	CcSEcCtD
Lenalidomide—Sinusitis—Epirubicin—thyroid cancer	0.000121	0.000369	CcSEcCtD
Lenalidomide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000121	0.000368	CcSEcCtD
Lenalidomide—Agranulocytosis—Epirubicin—thyroid cancer	0.000121	0.000367	CcSEcCtD
Lenalidomide—Pneumonia—Doxorubicin—thyroid cancer	0.00012	0.000366	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CDK1—thyroid cancer	0.00012	0.00416	CbGpPWpGaD
Lenalidomide—Infestation NOS—Doxorubicin—thyroid cancer	0.00012	0.000364	CcSEcCtD
Lenalidomide—Infestation—Doxorubicin—thyroid cancer	0.00012	0.000364	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000119	0.00412	CbGpPWpGaD
Lenalidomide—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000119	0.000361	CcSEcCtD
Lenalidomide—Bradycardia—Epirubicin—thyroid cancer	0.000118	0.00036	CcSEcCtD
Lenalidomide—Renal failure—Doxorubicin—thyroid cancer	0.000118	0.000358	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000117	0.000357	CcSEcCtD
Lenalidomide—Haemoglobin—Epirubicin—thyroid cancer	0.000117	0.000355	CcSEcCtD
Lenalidomide—Stomatitis—Doxorubicin—thyroid cancer	0.000117	0.000355	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000117	0.00404	CbGpPWpGaD
Lenalidomide—Rhinitis—Epirubicin—thyroid cancer	0.000117	0.000354	CcSEcCtD
Lenalidomide—Conjunctivitis—Doxorubicin—thyroid cancer	0.000116	0.000354	CcSEcCtD
Lenalidomide—Urinary tract infection—Doxorubicin—thyroid cancer	0.000116	0.000354	CcSEcCtD
Lenalidomide—Haemorrhage—Epirubicin—thyroid cancer	0.000116	0.000353	CcSEcCtD
Lenalidomide—Hepatitis—Epirubicin—thyroid cancer	0.000116	0.000353	CcSEcCtD
Lenalidomide—Hypoaesthesia—Epirubicin—thyroid cancer	0.000116	0.000351	CcSEcCtD
Lenalidomide—Pharyngitis—Epirubicin—thyroid cancer	0.000115	0.00035	CcSEcCtD
Lenalidomide—Sweating—Doxorubicin—thyroid cancer	0.000115	0.000349	CcSEcCtD
Lenalidomide—Urinary tract disorder—Epirubicin—thyroid cancer	0.000115	0.000349	CcSEcCtD
Lenalidomide—Oedema peripheral—Epirubicin—thyroid cancer	0.000114	0.000348	CcSEcCtD
Lenalidomide—Haematuria—Doxorubicin—thyroid cancer	0.000114	0.000347	CcSEcCtD
Lenalidomide—Connective tissue disorder—Epirubicin—thyroid cancer	0.000114	0.000347	CcSEcCtD
Lenalidomide—Urethral disorder—Epirubicin—thyroid cancer	0.000114	0.000346	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000113	0.000344	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—thyroid cancer	0.000113	0.000343	CcSEcCtD
Lenalidomide—Sinusitis—Doxorubicin—thyroid cancer	0.000112	0.000341	CcSEcCtD
Lenalidomide—Visual impairment—Epirubicin—thyroid cancer	0.000112	0.00034	CcSEcCtD
Lenalidomide—Agranulocytosis—Doxorubicin—thyroid cancer	0.000112	0.00034	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000112	0.00387	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000111	0.00385	CbGpPWpGaD
Lenalidomide—Erythema multiforme—Epirubicin—thyroid cancer	0.00011	0.000334	CcSEcCtD
Lenalidomide—Bradycardia—Doxorubicin—thyroid cancer	0.000109	0.000333	CcSEcCtD
Lenalidomide—Eye disorder—Epirubicin—thyroid cancer	0.000109	0.00033	CcSEcCtD
Lenalidomide—Tinnitus—Epirubicin—thyroid cancer	0.000108	0.000329	CcSEcCtD
Lenalidomide—Haemoglobin—Doxorubicin—thyroid cancer	0.000108	0.000328	CcSEcCtD
Lenalidomide—Flushing—Epirubicin—thyroid cancer	0.000108	0.000328	CcSEcCtD
Lenalidomide—Cardiac disorder—Epirubicin—thyroid cancer	0.000108	0.000328	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—thyroid cancer	0.000108	0.000328	CcSEcCtD
Lenalidomide—Haemorrhage—Doxorubicin—thyroid cancer	0.000108	0.000327	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—thyroid cancer	0.000108	0.000327	CcSEcCtD
Lenalidomide—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000107	0.000325	CcSEcCtD
Lenalidomide—Pharyngitis—Doxorubicin—thyroid cancer	0.000107	0.000324	CcSEcCtD
Lenalidomide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000106	0.000323	CcSEcCtD
Lenalidomide—Oedema peripheral—Doxorubicin—thyroid cancer	0.000106	0.000322	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000106	0.000321	CcSEcCtD
Lenalidomide—Angiopathy—Epirubicin—thyroid cancer	0.000105	0.00032	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—thyroid cancer	0.000105	0.00032	CcSEcCtD
Lenalidomide—Immune system disorder—Epirubicin—thyroid cancer	0.000105	0.000319	CcSEcCtD
Lenalidomide—Mediastinal disorder—Epirubicin—thyroid cancer	0.000105	0.000318	CcSEcCtD
Lenalidomide—Chills—Epirubicin—thyroid cancer	0.000104	0.000317	CcSEcCtD
Lenalidomide—Arrhythmia—Epirubicin—thyroid cancer	0.000104	0.000315	CcSEcCtD
Lenalidomide—Visual impairment—Doxorubicin—thyroid cancer	0.000104	0.000315	CcSEcCtD
Lenalidomide—Alopecia—Epirubicin—thyroid cancer	0.000103	0.000312	CcSEcCtD
Lenalidomide—Mental disorder—Epirubicin—thyroid cancer	0.000102	0.000309	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—thyroid cancer	0.000102	0.000309	CcSEcCtD
Lenalidomide—Malnutrition—Epirubicin—thyroid cancer	0.000101	0.000307	CcSEcCtD
Lenalidomide—Erythema—Epirubicin—thyroid cancer	0.000101	0.000307	CcSEcCtD
Lenalidomide—Eye disorder—Doxorubicin—thyroid cancer	0.0001	0.000305	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.0001	0.00348	CbGpPWpGaD
Lenalidomide—Tinnitus—Doxorubicin—thyroid cancer	0.0001	0.000305	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—thyroid cancer	9.98e-05	0.000303	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—thyroid cancer	9.98e-05	0.000303	CcSEcCtD
Lenalidomide—Flatulence—Epirubicin—thyroid cancer	9.97e-05	0.000303	CcSEcCtD
Lenalidomide—Tension—Epirubicin—thyroid cancer	9.93e-05	0.000302	CcSEcCtD
Lenalidomide—Dysgeusia—Epirubicin—thyroid cancer	9.91e-05	0.000301	CcSEcCtD
Lenalidomide—Nervousness—Epirubicin—thyroid cancer	9.83e-05	0.000299	CcSEcCtD
Lenalidomide—Back pain—Epirubicin—thyroid cancer	9.79e-05	0.000297	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—thyroid cancer	9.76e-05	0.000296	CcSEcCtD
Lenalidomide—Muscle spasms—Epirubicin—thyroid cancer	9.73e-05	0.000296	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—thyroid cancer	9.71e-05	0.000295	CcSEcCtD
Lenalidomide—Mediastinal disorder—Doxorubicin—thyroid cancer	9.69e-05	0.000294	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	9.66e-05	0.00335	CbGpPWpGaD
Lenalidomide—Chills—Doxorubicin—thyroid cancer	9.65e-05	0.000293	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NRG1—thyroid cancer	9.63e-05	0.00334	CbGpPWpGaD
Lenalidomide—Arrhythmia—Doxorubicin—thyroid cancer	9.61e-05	0.000292	CcSEcCtD
Lenalidomide—Vision blurred—Epirubicin—thyroid cancer	9.54e-05	0.00029	CcSEcCtD
Lenalidomide—Alopecia—Doxorubicin—thyroid cancer	9.5e-05	0.000289	CcSEcCtD
Lenalidomide—Mental disorder—Doxorubicin—thyroid cancer	9.42e-05	0.000286	CcSEcCtD
Lenalidomide—Ill-defined disorder—Epirubicin—thyroid cancer	9.39e-05	0.000285	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—thyroid cancer	9.36e-05	0.000284	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—thyroid cancer	9.36e-05	0.000284	CcSEcCtD
Lenalidomide—Anaemia—Epirubicin—thyroid cancer	9.35e-05	0.000284	CcSEcCtD
Lenalidomide—Agitation—Epirubicin—thyroid cancer	9.3e-05	0.000283	CcSEcCtD
Lenalidomide—Flatulence—Doxorubicin—thyroid cancer	9.22e-05	0.00028	CcSEcCtD
Lenalidomide—Tension—Doxorubicin—thyroid cancer	9.19e-05	0.000279	CcSEcCtD
Lenalidomide—Dysgeusia—Doxorubicin—thyroid cancer	9.17e-05	0.000279	CcSEcCtD
Lenalidomide—Malaise—Epirubicin—thyroid cancer	9.12e-05	0.000277	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—thyroid cancer	9.09e-05	0.000276	CcSEcCtD
Lenalidomide—Vertigo—Epirubicin—thyroid cancer	9.09e-05	0.000276	CcSEcCtD
Lenalidomide—Syncope—Epirubicin—thyroid cancer	9.07e-05	0.000276	CcSEcCtD
Lenalidomide—Leukopenia—Epirubicin—thyroid cancer	9.06e-05	0.000275	CcSEcCtD
Lenalidomide—Back pain—Doxorubicin—thyroid cancer	9.06e-05	0.000275	CcSEcCtD
Lenalidomide—Muscle spasms—Doxorubicin—thyroid cancer	9e-05	0.000273	CcSEcCtD
Lenalidomide—Palpitations—Epirubicin—thyroid cancer	8.94e-05	0.000272	CcSEcCtD
Lenalidomide—Loss of consciousness—Epirubicin—thyroid cancer	8.89e-05	0.00027	CcSEcCtD
Lenalidomide—Cough—Epirubicin—thyroid cancer	8.83e-05	0.000268	CcSEcCtD
Lenalidomide—Vision blurred—Doxorubicin—thyroid cancer	8.82e-05	0.000268	CcSEcCtD
Lenalidomide—Hypertension—Epirubicin—thyroid cancer	8.74e-05	0.000265	CcSEcCtD
Lenalidomide—Ill-defined disorder—Doxorubicin—thyroid cancer	8.69e-05	0.000264	CcSEcCtD
Lenalidomide—Anaemia—Doxorubicin—thyroid cancer	8.65e-05	0.000263	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TERT—thyroid cancer	8.64e-05	0.003	CbGpPWpGaD
Lenalidomide—Myalgia—Epirubicin—thyroid cancer	8.61e-05	0.000262	CcSEcCtD
Lenalidomide—Arthralgia—Epirubicin—thyroid cancer	8.61e-05	0.000262	CcSEcCtD
Lenalidomide—Chest pain—Epirubicin—thyroid cancer	8.61e-05	0.000262	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—thyroid cancer	8.6e-05	0.000261	CcSEcCtD
Lenalidomide—Anxiety—Epirubicin—thyroid cancer	8.58e-05	0.000261	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	8.55e-05	0.00026	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	8.53e-05	0.00296	CbGpPWpGaD
Lenalidomide—Discomfort—Epirubicin—thyroid cancer	8.51e-05	0.000259	CcSEcCtD
Lenalidomide—Malaise—Doxorubicin—thyroid cancer	8.44e-05	0.000257	CcSEcCtD
Lenalidomide—Dry mouth—Epirubicin—thyroid cancer	8.42e-05	0.000256	CcSEcCtD
Lenalidomide—Vertigo—Doxorubicin—thyroid cancer	8.41e-05	0.000256	CcSEcCtD
Lenalidomide—Syncope—Doxorubicin—thyroid cancer	8.4e-05	0.000255	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—thyroid cancer	8.38e-05	0.000255	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	8.36e-05	0.0029	CbGpPWpGaD
Lenalidomide—Confusional state—Epirubicin—thyroid cancer	8.33e-05	0.000253	CcSEcCtD
Lenalidomide—Palpitations—Doxorubicin—thyroid cancer	8.27e-05	0.000251	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—HIF1A—thyroid cancer	8.27e-05	0.00287	CbGpPWpGaD
Lenalidomide—Oedema—Epirubicin—thyroid cancer	8.26e-05	0.000251	CcSEcCtD
Lenalidomide—Loss of consciousness—Doxorubicin—thyroid cancer	8.23e-05	0.00025	CcSEcCtD
Lenalidomide—Infection—Epirubicin—thyroid cancer	8.2e-05	0.000249	CcSEcCtD
Lenalidomide—Cough—Doxorubicin—thyroid cancer	8.17e-05	0.000248	CcSEcCtD
Lenalidomide—Shock—Epirubicin—thyroid cancer	8.12e-05	0.000247	CcSEcCtD
Lenalidomide—Nervous system disorder—Epirubicin—thyroid cancer	8.1e-05	0.000246	CcSEcCtD
Lenalidomide—Thrombocytopenia—Epirubicin—thyroid cancer	8.08e-05	0.000246	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—thyroid cancer	8.08e-05	0.000246	CcSEcCtD
Lenalidomide—Tachycardia—Epirubicin—thyroid cancer	8.06e-05	0.000245	CcSEcCtD
Lenalidomide—Skin disorder—Epirubicin—thyroid cancer	8.02e-05	0.000244	CcSEcCtD
Lenalidomide—Hyperhidrosis—Epirubicin—thyroid cancer	7.98e-05	0.000243	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—thyroid cancer	7.97e-05	0.000242	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—thyroid cancer	7.97e-05	0.000242	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—thyroid cancer	7.97e-05	0.000242	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—thyroid cancer	7.94e-05	0.000241	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	7.92e-05	0.00024	CcSEcCtD
Lenalidomide—Discomfort—Doxorubicin—thyroid cancer	7.87e-05	0.000239	CcSEcCtD
Lenalidomide—Anorexia—Epirubicin—thyroid cancer	7.87e-05	0.000239	CcSEcCtD
Lenalidomide—PTGS2—Disease—TRIM24—thyroid cancer	7.83e-05	0.00272	CbGpPWpGaD
Lenalidomide—Dry mouth—Doxorubicin—thyroid cancer	7.79e-05	0.000237	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—MINPP1—thyroid cancer	7.72e-05	0.00268	CbGpPWpGaD
Lenalidomide—Hypotension—Epirubicin—thyroid cancer	7.72e-05	0.000234	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—thyroid cancer	7.7e-05	0.000234	CcSEcCtD
Lenalidomide—Oedema—Doxorubicin—thyroid cancer	7.64e-05	0.000232	CcSEcCtD
Lenalidomide—Infection—Doxorubicin—thyroid cancer	7.59e-05	0.000231	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	7.52e-05	0.000229	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—thyroid cancer	7.52e-05	0.000228	CcSEcCtD
Lenalidomide—Nervous system disorder—Doxorubicin—thyroid cancer	7.49e-05	0.000228	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—thyroid cancer	7.48e-05	0.000227	CcSEcCtD
Lenalidomide—Insomnia—Epirubicin—thyroid cancer	7.47e-05	0.000227	CcSEcCtD
Lenalidomide—Tachycardia—Doxorubicin—thyroid cancer	7.46e-05	0.000227	CcSEcCtD
Lenalidomide—Skin disorder—Doxorubicin—thyroid cancer	7.42e-05	0.000225	CcSEcCtD
Lenalidomide—Paraesthesia—Epirubicin—thyroid cancer	7.41e-05	0.000225	CcSEcCtD
Lenalidomide—Hyperhidrosis—Doxorubicin—thyroid cancer	7.39e-05	0.000224	CcSEcCtD
Lenalidomide—PTGS2—Disease—CHST14—thyroid cancer	7.37e-05	0.00255	CbGpPWpGaD
Lenalidomide—Dyspnoea—Epirubicin—thyroid cancer	7.36e-05	0.000224	CcSEcCtD
Lenalidomide—Somnolence—Epirubicin—thyroid cancer	7.34e-05	0.000223	CcSEcCtD
Lenalidomide—Anorexia—Doxorubicin—thyroid cancer	7.28e-05	0.000221	CcSEcCtD
Lenalidomide—Dyspepsia—Epirubicin—thyroid cancer	7.27e-05	0.000221	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	7.2e-05	0.0025	CbGpPWpGaD
Lenalidomide—Decreased appetite—Epirubicin—thyroid cancer	7.18e-05	0.000218	CcSEcCtD
Lenalidomide—Hypotension—Doxorubicin—thyroid cancer	7.14e-05	0.000217	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Epirubicin—thyroid cancer	7.13e-05	0.000217	CcSEcCtD
Lenalidomide—Fatigue—Epirubicin—thyroid cancer	7.12e-05	0.000216	CcSEcCtD
Lenalidomide—Constipation—Epirubicin—thyroid cancer	7.06e-05	0.000215	CcSEcCtD
Lenalidomide—Pain—Epirubicin—thyroid cancer	7.06e-05	0.000215	CcSEcCtD
Lenalidomide—PTGS2—Disease—TRIM33—thyroid cancer	6.98e-05	0.00242	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	6.96e-05	0.000212	CcSEcCtD
Lenalidomide—Insomnia—Doxorubicin—thyroid cancer	6.91e-05	0.00021	CcSEcCtD
Lenalidomide—Paraesthesia—Doxorubicin—thyroid cancer	6.86e-05	0.000208	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	6.85e-05	0.00237	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—BRAF—thyroid cancer	6.85e-05	0.00237	CbGpPWpGaD
Lenalidomide—Dyspnoea—Doxorubicin—thyroid cancer	6.81e-05	0.000207	CcSEcCtD
Lenalidomide—Feeling abnormal—Epirubicin—thyroid cancer	6.8e-05	0.000207	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—thyroid cancer	6.79e-05	0.000206	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Epirubicin—thyroid cancer	6.75e-05	0.000205	CcSEcCtD
Lenalidomide—Dyspepsia—Doxorubicin—thyroid cancer	6.73e-05	0.000204	CcSEcCtD
Lenalidomide—Decreased appetite—Doxorubicin—thyroid cancer	6.64e-05	0.000202	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	6.6e-05	0.0002	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—thyroid cancer	6.59e-05	0.0002	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—NDUFA13—thyroid cancer	6.56e-05	0.00227	CbGpPWpGaD
Lenalidomide—Urticaria—Epirubicin—thyroid cancer	6.56e-05	0.000199	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—thyroid cancer	6.53e-05	0.000199	CcSEcCtD
Lenalidomide—Pain—Doxorubicin—thyroid cancer	6.53e-05	0.000199	CcSEcCtD
Lenalidomide—Body temperature increased—Epirubicin—thyroid cancer	6.53e-05	0.000198	CcSEcCtD
Lenalidomide—Abdominal pain—Epirubicin—thyroid cancer	6.53e-05	0.000198	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	6.37e-05	0.00221	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Doxorubicin—thyroid cancer	6.3e-05	0.000191	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Doxorubicin—thyroid cancer	6.25e-05	0.00019	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	6.2e-05	0.00215	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CHST14—thyroid cancer	6.17e-05	0.00214	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Epirubicin—thyroid cancer	6.08e-05	0.000185	CcSEcCtD
Lenalidomide—Urticaria—Doxorubicin—thyroid cancer	6.07e-05	0.000184	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—thyroid cancer	6.04e-05	0.000184	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—thyroid cancer	6.04e-05	0.000184	CcSEcCtD
Lenalidomide—Asthenia—Epirubicin—thyroid cancer	5.92e-05	0.00018	CcSEcCtD
Lenalidomide—Pruritus—Epirubicin—thyroid cancer	5.84e-05	0.000178	CcSEcCtD
Lenalidomide—Diarrhoea—Epirubicin—thyroid cancer	5.65e-05	0.000172	CcSEcCtD
Lenalidomide—Hypersensitivity—Doxorubicin—thyroid cancer	5.63e-05	0.000171	CcSEcCtD
Lenalidomide—Asthenia—Doxorubicin—thyroid cancer	5.48e-05	0.000167	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—MINPP1—thyroid cancer	5.47e-05	0.0019	CbGpPWpGaD
Lenalidomide—Dizziness—Epirubicin—thyroid cancer	5.46e-05	0.000166	CcSEcCtD
Lenalidomide—Pruritus—Doxorubicin—thyroid cancer	5.41e-05	0.000164	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	5.27e-05	0.00183	CbGpPWpGaD
Lenalidomide—Vomiting—Epirubicin—thyroid cancer	5.25e-05	0.00016	CcSEcCtD
Lenalidomide—Diarrhoea—Doxorubicin—thyroid cancer	5.23e-05	0.000159	CcSEcCtD
Lenalidomide—Rash—Epirubicin—thyroid cancer	5.21e-05	0.000158	CcSEcCtD
Lenalidomide—Dermatitis—Epirubicin—thyroid cancer	5.2e-05	0.000158	CcSEcCtD
Lenalidomide—Headache—Epirubicin—thyroid cancer	5.17e-05	0.000157	CcSEcCtD
Lenalidomide—Dizziness—Doxorubicin—thyroid cancer	5.05e-05	0.000154	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CCND1—thyroid cancer	5e-05	0.00173	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HPGD—thyroid cancer	4.97e-05	0.00172	CbGpPWpGaD
Lenalidomide—Nausea—Epirubicin—thyroid cancer	4.9e-05	0.000149	CcSEcCtD
Lenalidomide—Vomiting—Doxorubicin—thyroid cancer	4.86e-05	0.000148	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PTEN—thyroid cancer	4.82e-05	0.00167	CbGpPWpGaD
Lenalidomide—Rash—Doxorubicin—thyroid cancer	4.82e-05	0.000146	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—thyroid cancer	4.81e-05	0.000146	CcSEcCtD
Lenalidomide—Headache—Doxorubicin—thyroid cancer	4.79e-05	0.000145	CcSEcCtD
Lenalidomide—PTGS2—Disease—TCF7L1—thyroid cancer	4.66e-05	0.00162	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NDUFA13—thyroid cancer	4.65e-05	0.00161	CbGpPWpGaD
Lenalidomide—Nausea—Doxorubicin—thyroid cancer	4.54e-05	0.000138	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—CHST14—thyroid cancer	4.37e-05	0.00152	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	4.33e-05	0.0015	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	4.32e-05	0.0015	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	4.32e-05	0.0015	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NRAS—thyroid cancer	4.3e-05	0.00149	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	4.25e-05	0.00147	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	4.2e-05	0.00146	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	4.18e-05	0.00145	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.03e-05	0.0014	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	4e-05	0.00139	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KRAS—thyroid cancer	3.7e-05	0.00128	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HPGD—thyroid cancer	3.52e-05	0.00122	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TPR—thyroid cancer	3.41e-05	0.00118	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	3.4e-05	0.00118	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PRKAR1A—thyroid cancer	3.35e-05	0.00116	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—thyroid cancer	3.29e-05	0.00114	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.24e-05	0.00112	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	3.21e-05	0.00111	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MEN1—thyroid cancer	3.21e-05	0.00111	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HRAS—thyroid cancer	3.15e-05	0.00109	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	3.07e-05	0.00107	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	2.97e-05	0.00103	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TPR—thyroid cancer	2.86e-05	0.00099	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.86e-05	0.00099	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PRKAR1A—thyroid cancer	2.81e-05	0.000974	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—thyroid cancer	2.78e-05	0.000963	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.72e-05	0.000942	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CALCA—thyroid cancer	2.55e-05	0.000885	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.55e-05	0.000883	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.41e-05	0.000836	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDK1—thyroid cancer	2.31e-05	0.000801	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.28e-05	0.000789	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC5A5—thyroid cancer	2.14e-05	0.000741	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TPR—thyroid cancer	2.02e-05	0.000702	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.02e-05	0.000702	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PRKAR1A—thyroid cancer	1.99e-05	0.00069	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRG1—thyroid cancer	1.85e-05	0.000643	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—RXRA—thyroid cancer	1.8e-05	0.000623	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.75e-05	0.000606	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.71e-05	0.000593	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TERT—thyroid cancer	1.67e-05	0.000577	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HIF1A—thyroid cancer	1.59e-05	0.000552	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.52e-05	0.000525	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BRAF—thyroid cancer	1.32e-05	0.000457	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—RXRA—thyroid cancer	1.27e-05	0.000441	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—thyroid cancer	1.13e-05	0.000393	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTEN—thyroid cancer	9.29e-06	0.000322	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRAS—thyroid cancer	8.29e-06	0.000287	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—thyroid cancer	8.04e-06	0.000279	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTEN—thyroid cancer	7.78e-06	0.00027	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—thyroid cancer	7.13e-06	0.000247	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—thyroid cancer	6.32e-06	0.000219	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—thyroid cancer	6.06e-06	0.00021	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTEN—thyroid cancer	5.52e-06	0.000191	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—thyroid cancer	5.35e-06	0.000186	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—thyroid cancer	4.48e-06	0.000155	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—thyroid cancer	3.18e-06	0.00011	CbGpPWpGaD
